REFERENCES

1. Allerguard Package Insert. July 2016.

2. Eichel A et al. Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis. Journal of Allergy. 2014.

3. Pawankar R et al. (eds) WAO White Book on Allergy 2011 World Allergy Organization.

4. http://www.everydayhealth.com/allergy-pictures/top-6-environmental-allergies.aspx#03.

5.Salapatek A et al. Ectoin®, a Novel, Non-Drug, Extremophile-Based Device, Relieves Allergic Rhinoconjunctivitis Symptoms in Patients in an Environmental Exposure Chamber Model. 2011 AAAAI Annual Meeting.

6. http://www.allergieratgeber.de/livocab/livocab-ectomed/

Proprietary name (and dosage form): Allerguard Allergy Nasal Spray. Marketed by: iNova Pharmaceuticals (Pty) Ltd. Reg.No.: 1952/001640/07. 15E Riley Road, Bedfordview, Gauteng, South Africa, 2007. Tel. No.: 011 087 0000 www.inovapharma.co.za. For full prescribing information, refer to the package insert. Further information available at www.allerguard.co.za or on request from iNova Pharmaceuticals. IN2331/16

www.pdf24.org    Send article as PDF